Evidence map›Paper›PMID 32228700›Full record

ArticleHarm reduction journal2020

Prescription opioid injection among young people who inject drugs in New York City: a mixed-methods description and associations with hepatitis C virus infection and overdose.

Pedro Mateu-Gelabert, Honoria Guarino, Jon E Zibbell, Jennifer Teubl, Chunki Fong, Elizabeth Goodbody, Brian Edlin, Carli Salvati, Samuel R Friedman

Abstract read
In one paragraph

Article in Harm reduction journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pedro Mateu-GelabertCUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health (ISPH), 55 West 125th Street, New York, NY, 10027, USA. pedro.mateu-gelabert@sph.cuny.edu.
Honoria GuarinoCUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health (ISPH), 55 West 125th Street, New York, NY, 10027, USA.
Jon E ZibbellRTI International, 2987 Clairmont Road, Century Plaza 1, Suite 400, Atlanta, GA, 30329-4434, USA.
Jennifer TeublNational Development Research Institutes, Inc., 71 West 23rd St, New York, NY, 10010, USA.
Chunki FongCUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health (ISPH), 55 West 125th Street, New York, NY, 10027, USA.
Elizabeth GoodbodyCUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health (ISPH), 55 West 125th Street, New York, NY, 10027, USA.
Brian EdlinIndependent Consultant, New York, NY, USA.
Carli SalvatiCUNY Graduate School of Public Health and Health Policy, Institute for Implementation Science in Population Health (ISPH), 55 West 125th Street, New York, NY, 10027, USA.
Samuel R FriedmanNYU School of Medicine, 550 First Avenue, New York, NY, 10016, USA.

Funding

Transdisciplinary Theoretical Svnthesis and Development CoreP30DA011041 · NIDA · NEW YORK UNIVERSITY · PI Holly Hagan, Courtney McKnight · 1998 to 2026
$38.9M
The Staying Safe Intervention: Preventing HCV among Young Opioid InjectorsR01DA041501 · NIDA · NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES, INC. · PI GUARINO, HONORIA M, MATEU-GELABERT, PEDRO · 2016 to 2020
$3.6M
HIV, HCV and STI Risk Associated with Nonmedical Use of Prescription OpioidsR01DA035146 · NIDA · NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES, INC. · PI MATEU-GELABERT, PEDRO · 2013 to 2017
$2.9M
Accessible Care Intervention for Engaging People who Inject Illicit Drugs (PWID) in Hepatitis C CareR01DA041298 · NIDA · NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES, INC. · PI MARKS, KRISTEN M, MATEU-GELABERT, PEDRO · 2016 to 2020
$2.8M
NIDA NIH HHS P30 DA011041NIDA NIH HHS R01 DA035146NIDA NIH HHS R01DA035146NIDA NIH HHS R01 DA041298NIDA NIH HHS R01 DA041501
6 · The paper itself

Abstract

aimEvidence is emerging that prescription opioid (PO) injection is associated with increased health risks. This mixed-methods study compares the mechanics of PO and heroin injection and examines the demographic and drug-related correlates of lifetime PO injection in a sample of young people who inject drugs (PWID) in New York City (NYC).

methodsQualitative analysis of 46 semi-structured interviews with young adult opioid users ages 18-32. Interview segments describing PO injection were analyzed for common themes. Quantitative analysis of structured interviews with 539 young adult opioid users ages 18-29 recruited via respondent-driven sampling (RDS). Analyses are based on the subsample of 353 participants (65%) who reported having ever injected drugs. All variables were assessed via self-report, except hepatitis C virus status, which was established via rapid antibody testing.

resultsParticipants described injecting POs and reported that preparing abuse-deterrent pills for injection is especially cumbersome, requiring extended manipulation and large amounts of water. Injecting POs, in contrast to injecting heroin, requires repeated injections per injection episode. Among RDS-recruited participants, the majority of injectors reported injecting POs, sporadically (33%) or regularly (26%), but often infrequently (≤ 7 days/month). In separate multivariable analyses controlling for syringe- and cooker-sharing, ever injecting POs was a significant predictor of testing HCV antibody-positive (AOR = 2.97) and lifetime experience of non-fatal overdose (AOR = 2.51). Ever injecting POs was independently associated with lifetime homelessness (AOR = 2.93) and having grown up in a middle-income ($51,000-100,000/year vs. ≤ $50,000/year; AOR = 1.86) or a high-income household (> $100,000/year vs. ≤ $50,000/year; AOR = 2.54).

conclusionsEven in an urban environment like NYC with widespread heroin access, most young PWID have injected POs, although less frequently than heroin. PO injection involves practices that are known to increase risk for blood-borne viral infection (e.g., repeated injections) and predicted testing HCV-positive, as well as overdose. PO injection may also serve as a marker for a subgroup of PWID at elevated risk for multiple drug use-related comorbidities. Programs that provide prevention services to PWID need to tailor harm reduction measures and messaging to the specific practices and harms associated with the injection of POs.

Indexed as

AdolescentAdultAnalgesics, OpioidComorbidityDrug OverdoseFemaleHepatitis CHumansInterviews as TopicMaleNew York CityPrescription Drug MisuseSubstance Abuse, IntravenousYoung AdultAnalgesics, OpioidDrug overdoseHepatitis C virus (HCV) infectionHeroinPrescription opioid injectionPrescription opioid misuseYoung PWID

Identifiers

PMID32228700
PMCPMC7106794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.